Company Filing History:
Years Active: 2020-2023
Title: Céline Deraison-Manuel: Innovator in Gut Inflammatory Disease Therapies
Introduction
Céline Deraison-Manuel is a prominent inventor based in Toulouse, France. He has made significant contributions to the field of therapy for gut inflammatory diseases. With a total of 2 patents, his work focuses on innovative methods to treat conditions such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).
Latest Patents
Céline's latest patents include a method of treating inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), or gluten hypersensitivity by administering an elastase 2A (ELA2A) inhibitor. This invention addresses the therapy of gut inflammatory diseases, demonstrating that ELA2A, secreted by epithelial cells, is over-expressed in IBD conditions. This overexpression degrades tight junction proteins and controls cytokine expression, leading to a pro-inflammatory phenotype. The research indicates that ELA2A over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. Notably, the increased CXCL-8 protein release is inhibited by ELAFIN in a dose-dependent manner. The invention also relates to inhibitors of Elastase ELA2A for treating various inflammatory bowel diseases, including Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.
Career Highlights
Céline has worked with esteemed institutions such as Université Toulouse III – Paul Sabatier and the Centre National de la Recherche Scientifique. His research has significantly advanced the understanding and treatment of gut inflammatory diseases.
Collaborations
Céline has collaborated with notable colleagues, including Nathalie Vergnolle and Corinne Rolland, contributing to the advancement of therapeutic strategies in his field.
Conclusion
Céline Deraison-Manuel's innovative work in the treatment of gut inflammatory diseases showcases his dedication to improving patient outcomes through scientific research and invention. His contributions are vital in the ongoing battle against these challenging health conditions.